SGS India

  Most organisations are moving faster on AI than on governing it. A recent industry report found that 93% of organisations already use AI, yet only 7% have embedded formal governance controls. That gap is where the compliance risk sits. Writing policies alone rarely closes a gap like this. Teams need to understand how to apply governance principles in real time, i.e., when they design, deploy, or use an AI system. This is where AI assurance training earns its place, turning abstract concepts about risk, fairness, or accountability into practical decisions people can make on the job.  For organisations pursuing AI management systems or preparing for the EU AI Act, this level of readiness is no longer optional; it becomes the operating foundation that every audit and certification depends on. AI assurance training and its role in ISO/IEC 42001 compliance AI assurance training gives employees, managers, and governance teams practical skills, not just high‑level awareness. It hel...

  Medical device manufacturers operate where quality, patient safety, and regulatory compliance directly decide market access. As global regulatory expectations tighten, organizations pursuing certification often discover that implementing ISO 13485 demands changing how the business actually runs.  Many companies underestimate this shift, and the result shows up later as delays, audit findings, or repeated corrective actions. The ISO 13485 certification challenges that follow are less about the standard being unreasonable and more about implementation gaps that are entirely fixable once identified.  This piece walks through the most common ones and what closes them. Why ISO 13485 Matters for Medical Device Manufacturers ISO 13485 defines the framework for a medical device quality management system (QMS). It helps organizations consistently meet regulatory and customer requirements. The standard supports product quality, patient safety, and regulatory compliance. It also e...

  Sustainability reporting has reached an inflection point for several organizations. What was once prepared primarily for investors is now influencing financing decisions, customer relationships, procurement requirements, and regulatory oversight. The question now is whether a company’s ESG performance can withstand independent verification. That shift changes the conversation around ESG advisory services . Their value lies not in producing another sustainability report, but in helping organizations build the governance, controls, and data confidence that credible reporting depends on. For companies navigating ESG compliance in India, assurance readiness is quickly becoming a business capability rather than a reporting exercise. Where Business Risk Really Lies Most organizations already collect sustainability data. The greater challenge is demonstrating that the information is reliable. Data gathered through spreadsheets, emails, or disconnected operational systems may support ann...

  For food manufacturers, certification is more than a compliance exercise. It is a signal of trust that enables access to global retailers, export markets, and increasingly demanding supply chains. Every revision of a food safety scheme matters because it shapes what buyers and certification bodies will soon expect. The release of FSSC 22000 Version 7 does exactly that. The updated version was released in May 2026 and clearly sets out the way forward. Version 6 certifications will be valid until April 30, 2027, while the transition audits are going to happen from May 1, 2027 to April 30, 2028. It provides an excellent chance for certified companies to enhance their food safety management systems in advance of a tightening audit schedule and increasing demand for professional auditors. The Certificate on Which You Rely Has an Expiry Date Now A valid certification implies business as usual; however, the transition period alters this perception. Organizations that have scheduled audi...

  For many Indian medical device manufacturers, growth increasingly means looking beyond domestic markets. Opportunities in the European Union, the United States, and other regulated healthcare markets are expanding, but so are expectations around product quality, patient safety, and regulatory compliance. A medical device may perform well in testing, but if the manufacturer cannot consistently demonstrate quality throughout design, production, and post-market activities, market access can quickly become challenging. The medical device industry has seen several high‑profile recalls over the years, often driven not just by product failures but by weak quality management and poor risk assessment. These situations highlight an important lesson: quality cannot be inspected into a product at the end of production. It must be built into every stage of the process. In many cases, recalls are not caused by a single manufacturing defect. They often stem from gaps in documentation, supplier ...